Yonhap Infomax NewsNov 5
Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit to KRW 24.1 billion, missing market expectations due to the absence of milestone revenue from Lazertinib, with shares falling over 3%.
#YonhapInfomax #YuhanCorp #OperatingProfit #Q3Earnings #Lazertinib #MarketExpectations #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=89350
Yuhan Corp. Reports 55.7% Drop in Q3 Operating Profit to KRW 24.1 Billion, Misses Market Expectations (Update)

Yuhan Corp. reported a 55.7% year-on-year drop in Q3 operating profit to KRW 24.1 billion, missing market expectations due to the absence of milestone revenue from Lazertinib, with shares falling over 3%.

Yonhap Infomax
Yonhap Infomax NewsJul 30, 2025
Yuhan Corp. reported a 190% surge in Q2 operating profit to 45.6 billion won, driven by milestone payments and royalties from its cancer drug Lazertinib, with results meeting market expectations.
#YonhapInfomax #YuhanCorp #OperatingProfit #Lazertinib #MilestonePayment #Q2Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=74532
Yuhan Corp. Posts Q2 Operating Profit of 45.6 Billion Won, Up 190%—'Milestone Payment from Lazertinib Reflected' (Comprehensive)

Yuhan Corp. reported a 190% surge in Q2 operating profit to 45.6 billion won, driven by milestone payments and royalties from its cancer drug Lazertinib, with results meeting market expectations.

Yonhap Infomax